• About us
• Contact

Advertisement

Organisation › Details

Sofinnova Telethon Fund I

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Headquartered in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. *

 

	Start	2019-10-17 existent
	Group	Sofinnova (Group)
	Industry	venture capital
	Industry 2	cell therapy
	Person	Papiernik, Antoine (Sofinnova Partners 201703 Managing Partner + Chairman joined 1997)
	Region	Paris
	Country	France
	City	n. a.
		Address record changed: 2019-10-19
Basic data	Employees	n. a.
		* Document for »About Section«: Sofinnova Partners. (10/17/19). "Press Release: Sofinnova Partners Raises €333 Million Capital IX Early-stage Healthcare Fund". Paris.
		Record changed: 2024-02-12

Advertisement

More documents for Sofinnova (Group)

• [1] Cure51 SAS. (3/20/24). "Press Release: Cure51 Raises a €15 Million Seed Round to Harness the Natural Power of Cancer Survivors to Develop First-in-Class Treatments and Transform Cancer into a Curable Disease". Paris....
• [2] Biotimus SAS. (2/20/24). "Press Release: Ex-Google DeepMind and Owkin Scientists Team up to Create Bioptimus to Build the First Universal AI Foundation Model for Biology"....
• [3] GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris....
• [4] Disco Pharmaceuticals GmbH. (1/16/24). "Press Release: Disco Pharmaceuticals Launches as the Surfaceome Company with EUR 20 Million in Seed Financing". Cologne & Zurich....
• [5] Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups". Paris....
• [6] Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners and Gustave Roussy Forge Strategic Alliance to Boost Oncology Startup Acceleration in France". Paris....
• [7] Sofinnova Partners. (12/5/23). "Press Release: Sofinnova Partners Unveils Sofinnova.AI – a Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment practice". Paris....
• [8] GenSight Biologics S.A.. (11/21/23). "Press Release: GenSight Biologics Announces a Successful Offering for an Amount of approximately €4.7 Million". Paris....
• [9] T-Therapeutics Ltd.. (11/15/23). "Press Release: T-Therapeutics Raises £48 Million Series A for Development of Next Generation TCR Therapeutics to Transform Cancer Treatment". Cambridge....
• [10] Nuage Therapeutics. (6/20/23). "Press Release: Nuage Therapeutics Raises €12M in Seed Financing Led by Sofinnova Partners and Asabys". Barcelona....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.